Jim Vail is the Director of New Business Development at Heracles Pharmaceuticals.  Jim’s professional experience includes more than 14 years in the healthcare industry in management roles at Johnson & Johnson’s Animas Corporation and most recently as Director of Development for Children with Diabetes, a non-profit organization helping people and families better manage type 1 diabetes.  Before joining Animas, Jim worked at CNBC Business News for over a decade as a coordinating producer in CNBC’s Washington, DC bureau covering the FDA, the SEC, OPEC, the Federal Reserve and the White House.

As a key team member of Heracles Pharmaceuticals, Jim’s goal and passion is to support the parent company’s important mission of “reducing the harm caused by smoking.”  Jim will present X-22, an innovative smoking cessation aid in development with an active IND with the FDA.  X-22 is made with the world’s lowest nicotine tobacco and is the first and only smoking cessation product in the form of a combustible cigarette.  To date, more than a dozen independent Phase II and Phase III clinical trials have shown that X-22 is the world’s most effective smoking cessation aid.